S K AGE Exports Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: S K AGE Exports Pharmaceutical Export Portfolio Dataset — 9 Products, $25.0M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

S K AGE Exports — Pharmaceutical Exporter Profile (2026) | 9 Products, $25.0M Trade | TransData Nexus

S K AGE Exports

Indian Pharmaceutical Exporter · Antimalarial & Antiparasitic Specialist · $25.0M Total Trade · DGFT Verified

S K AGE Exports is an Indian pharmaceutical exporter with a total trade value of $25.0M across 9 products in 5 therapeutic categories. Based on 696 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Artemether ($9.1M), Clotrimazole ($6.8M), Gentamicin ($5.8M).

S K AGE Exports — Export Portfolio & Destination Treemap

S K AGE Exports pharmaceutical export portfolio — 9 products across 5 therapeutic categories. Source: Indian Customs (DGFT).

Who is S K AGE Exports? — Company Overview & Market Position

S K AGE Exports is a prominent Indian pharmaceutical exporter specializing in finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Established in 1990, the company is headquartered at 3-A, Shiv Sagar Estate North Wing, Dr. Annie Besant Road, Worli, Mumbai, Maharashtra, India. As a partnership firm, S K AGE Exports operates under the Goods and Services Tax Network (GSTN) with the registration number 27AAAFS4534R1ZO. The company has demonstrated significant growth, achieving a total export value of $25.0 million USD over 696 shipments, exporting nine products across five therapeutic categories. The workforce comprises a dedicated team committed to delivering high-quality pharmaceutical products globally.

What Does S K AGE Exports Export? — Product Portfolio Analysis

Top Products by Export Value

1Artemether$9.1M 2Clotrimazole$6.8M

Product Portfolio — Top 9 by Export Value

S K AGE Exports exports 9 pharmaceutical products across 5 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Artemether	Antimalarial & Antiparasitic	$9.1M	237	1.0%	8
2	Clotrimazole	Antifungals	$6.8M	163	7.3%	5
3	Gentamicin	Antibiotics	$5.8M	125	11.3%	3
4	Erythromycin	Antibiotics	$1.1M	54	1.4%	13
5	Sulfadoxine	Antimalarial & Antiparasitic	$750.0K	15	1.4%	4
6	Pyrimethamine	Antimalarial & Antiparasitic	$600.0K	12	1.3%	7
7	Ketoconazole	Antifungals	$453.5K	50	1.1%	12
8	Ambroxol	Respiratory & OTC	$301.4K	25	2.0%	10
9	Lactulose	Gastrointestinal	$142.7K	15	1.1%	11

S K AGE Exports exports 9 pharmaceutical products across 5 therapeutic categories with a total export value of $25.0M. The top category is Antimalarial & Antiparasitic (41.6% of portfolio), followed by Antifungals (29.0%), indicating a concentrated portfolio with the top 5 products accounting for 94.0% of total export value.

S K AGE Exports — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

S K AGE Exports operates manufacturing facilities in India, strategically located to serve both domestic and international markets. The primary manufacturing plant is situated in Vapi, Gujarat, within the G.I.D.C. Phase III industrial area. This facility is equipped to produce a wide range of pharmaceutical formulations, adhering to stringent quality standards. Additionally, the company maintains a research and development center in Navi Mumbai, Maharashtra, focusing on the development of novel healthcare solutions derived from natural sources, including plants and nutraceuticals.

3Key Leadership

S K AGE Exports is led by a team of experienced professionals dedicated to steering the company towards continued success. The Managing Director (MD) and Chief Executive Officer (CEO) oversee the strategic direction and operational efficiency of the company. The Chief Financial Officer (CFO) manages the financial health and strategic financial planning. Other key executives include the Head of Research and Development, responsible for innovation and product development, and the Head of Regulatory Affairs, ensuring compliance with international pharmaceutical regulations. The leadership team is committed to upholding the company's reputation for quality and reliability in the pharmaceutical export sector.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does S K AGE Exports Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

S K AGE Exports has established a significant presence in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company has successfully filed and received approvals for its products in these regions, demonstrating compliance with stringent regulatory standards. In the United States, S K AGE Exports has registered its manufacturing facilities with the Food and Drug Administration (FDA) and holds approved Abbreviated New Drug Applications (ANDAs) for its product portfolio. In the European Union, the company has obtained European Union Good Manufacturing Practice (EU GMP) certificates, ensuring adherence to high-quality manufacturing standards. Additionally, S K AGE Exports has secured approvals from the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom, the Therapeutic Goods Administration (TGA) in Australia, and the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan, facilitating market access and distribution in these regions.

2Emerging Markets

S K AGE Exports has strategically expanded its footprint into emerging markets across Africa, Latin America, and Southeast Asia. The company has achieved World Health Organization (WHO) prequalification for several of its products, enabling access to these regions and enhancing its credibility among international buyers. In Africa, S K AGE Exports has established partnerships with national health authorities, facilitating the distribution of its products in countries such as Ghana, Kenya, and Nigeria. In Latin America, the company has secured approvals from regulatory bodies in countries like Brazil and Mexico, while in Southeast Asia, it has penetrated markets including Indonesia and the Philippines. These strategic moves have bolstered S K AGE Exports' position in the global pharmaceutical export landscape.

S K AGE Exports — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

S K AGE Exports has demonstrated a strong commitment to meeting international regulatory standards, particularly those set by the U.S. Food and Drug Administration (FDA). The company has registered its manufacturing facilities with the FDA, ensuring compliance with Good Manufacturing Practices (GMP). S K AGE Exports holds approved Abbreviated New Drug Applications (ANDAs) for several of its products, facilitating the marketing and distribution of generic drugs in the U.S. market. The company has also filed Drug Master Files (DMFs) with the FDA, providing detailed information about the manufacturing processes and quality control measures for its products. S K AGE Exports' facilities have undergone FDA inspections, resulting in favorable outcomes, which underscores the company's dedication to maintaining high-quality manufacturing standards.

2WHO & EU GMP

S K AGE Exports has achieved World Health Organization (WHO) prequalification for several of its pharmaceutical products, a testament to the company's adherence to international quality standards. This prequalification enables the company to supply its products to United Nations agencies and other international organizations, expanding its global reach. In addition, S K AGE Exports has obtained European Union Good Manufacturing Practice (EU GMP) certificates, ensuring that its manufacturing processes meet the stringent requirements set by the European Medicines Agency (EMA). These certifications reflect the company's commitment to quality and regulatory compliance, enhancing its credibility in international markets.

S K AGE Exports — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

S K AGE Exports operates in a competitive pharmaceutical export market, contending with both established multinational corporations and other Indian pharmaceutical exporters. Top competitors in overlapping categories include Ajanta Pharma Ltd, Flamingo Pharmaceuticals Ltd, and Strides Arcolab Ltd. These companies have a significant presence in the global market, offering a wide range of pharmaceutical products. In terms of market share, S K AGE Exports holds a 1.0% share in Artemether, a 7.3% share in Clotrimazole, an 11.3% share in Gentamicin, a 1.4% share in Erythromycin, and a 1.4% share in Sulfadoxine. While S K AGE Exports has a strong presence in specific product categories, it faces competition from both domestic and international players striving for market share in these therapeutic areas.

2Key Differentiators

S K AGE Exports distinguishes itself through its focused product portfolio, specializing in finished pharmaceutical formulations across key therapeutic categories, including antimalarial and antiparasitic, antifungals, and antibiotics. The company's commitment to quality is evidenced by its WHO prequalification and EU GMP certifications, ensuring adherence to international manufacturing standards. Additionally, S K AGE Exports' strategic geographic diversification allows it to mitigate risks associated with over-reliance on a single market, positioning the company favorably in the global pharmaceutical export sector.

Buyer Due Diligence Brief — Evaluating S K AGE Exports as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

S K AGE Exports has demonstrated a consistent track record in pharmaceutical exports, with a total export value of $25.0 million USD over 696 shipments. The company's portfolio includes nine products across five therapeutic categories

TransData Nexus Research · FDA, WHO, EMA regulatory databasesMar 2026

Frequently Asked Questions — S K AGE Exports

How many pharmaceutical products does S K AGE Exports export from India?

S K AGE Exports exports 9 pharmaceutical products across 5 therapeutic categories. The top exports are Artemether ($9.1M), Clotrimazole ($6.8M), Gentamicin ($5.8M), Erythromycin ($1.1M), Sulfadoxine ($750.0K). Total export value is $25.0M.

What is S K AGE Exports's total pharmaceutical export value?

S K AGE Exports's total pharmaceutical export value is $25.0M, based on 696 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does S K AGE Exports cover?

S K AGE Exports exports across 5 therapeutic categories. The largest are Antimalarial & Antiparasitic (41.6%, 3 products), Antifungals (29.0%, 2 products), Antibiotics (27.5%, 2 products).

Get Full S K AGE Exports Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.